Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis

Patients with primary myelofibrosis (PMF) have a poorer prognosis than those with other subtypes of myeloproliferative neoplasms (MPNs). To investigate the relationship between gene mutations and the prognosis of Japanese PMF patients, we analyzed mutations in 72 regions located in 14 MPN-relevant genes ( CSF3R , MPL , JAK2 , CALR , DNMT3A , TET2 , EZH2 , ASXL1 , IDH1/2 , SRSF2 , SF3B1 , U2AF1 , and TP53 ) utilizing a target resequencing platform. In our cohort, ASXL1 mutations were more frequently detected in both overt and prefibrotic PMF patients than other mutations. The frequency of ASXL1 mutations was slightly higher among overt PMF patients than among prefibrotic PMF patients (44.6% vs 25.0%, FDR = 0.472). Decision tree classification algorithms revealed that ASXL1 , EZH2, and SRSF2 mutations were associated with a poor prognosis for overt PMF. Overall survival was significantly shorter in patients harboring ASXL1 , EZH2 , or SRSF2 mutations than in those without these mutations ( p = 0.03). These results suggest that, as reported in Western countries, MIPSS70 is applicable to Japanese PMF patients and ASXL1 , EZH2 , and SRSF2 mutations may be utilized as surrogate markers of a poor prognosis.